FDA Peptide Reclassification 2026: What It Means for Providers Is BPC 157 Banned? Oral vs. Injectable Forms Explained The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA July 2026 Peptide Meeting: What Patients Need to Know About Access, Approval, and Safety Meto blog